BiotechTube

HRF2105 patch + Loxoprofen patch + placebo

Phase 2UNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 31/100
31
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Analgesia and Anti-inflammatory of Osteoarthritis

Conditions

Analgesia and Anti-inflammatory of Osteoarthritis

Trial Timeline

Oct 1, 2023 → Dec 1, 2023

NCT ID
NCT06047483

About HRF2105 patch + Loxoprofen patch + placebo

HRF2105 patch + Loxoprofen patch + placebo is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Analgesia and Anti-inflammatory of Osteoarthritis. The current trial status is unknown. This product is registered under clinical trial identifier NCT06047483. Target conditions include Analgesia and Anti-inflammatory of Osteoarthritis.

What happened to similar drugs?

5 of 10 similar drugs in Analgesia and Anti-inflammatory of Osteoarthritis were approved

Approved (5) Terminated (0) Active (5)
✅Bupivacaine Liposome InjectionJiangsu Hengrui MedicineApproved
✅HTX-011 + Bupivacaine Hydrochloride + Ibuprofen + AcetaminophenHeron TherapeuticsApproved
✅Bupivacaine HClHeron TherapeuticsApproved
✅Bupivacaine liposome injectable suspension + Bupivacaine HCl without epinephrine via continuous infusionHeron TherapeuticsApproved
✅Bupivacaine Hydrochloride + Bupivacaine Hydrochloride + HTX-011 + Ibuprofen + AcetaminophenHeron TherapeuticsApproved
🔄Ibuprofen 600 mg Immediate Release/Extended Release CapletPfizerPhase 3
🔄HSK21542 Injection + Tramadol hydrochloride + placeboHaisco Pharmaceutical GroupPhase 3

Hype Score Breakdown

Clinical
12
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT06047483Phase 2UNKNOWN

Competing Products

20 competing products in Analgesia and Anti-inflammatory of Osteoarthritis

See all competitors
ProductCompanyStageHype Score
AcetaminophenJohnson & JohnsonPhase 2
42
Bupivacaine Liposome Injection T preparation + Bupivacaine Liposome Injection R preparationJiangsu Hengrui MedicinePhase 1
29
Bupivacaine Liposome InjectionJiangsu Hengrui MedicineApproved
50
Paracetamol injection + Normal Saline injection + Morhpine PCAJiangsu Hengrui MedicinePhase 2/3
38
Bupivacaine Liposome Injection + Bupivacaine Hydrochloride InjectionJiangsu Hengrui MedicinePhase 2
42
Org 28611 + morphine sulfate + PlaceboMerckPhase 2
27
oxycodone hydrochloride + oxycodone hydrochloride + oxycodone hydrochloride + oxycodone hydrochloride + marketed oxycodone hydrochloridePfizerPhase 1
29
Ibuprofen 600 mg Immediate Release/Extended Release CapletPfizerPhase 3
40
HSK21542 Injection + Tramadol hydrochloride + placeboHaisco Pharmaceutical GroupPhase 3
40
Experimental: stage I：HSK21542 0.4 μg/kg + Experimental: stage I：HSK21542 1 μg/kg + Experimental: stage I：HSK21542 0.5μg/kg + Experimental: stage I：HSK21542 1μg/kg + Experimental: stage II：HSK21542 0.5μg/kg + Experimental: stage II：HSK21542 1μg/kg + PlaceboHaisco Pharmaceutical GroupPhase 2
35
Stage I: HSK21542 0.5 μg/kg + Stage I: HSK21542 1 μg/kg + HSK21542 0.5 μg/kg + HSK21542 1 μg/kg + HSK21542 2 μg/kg + PlaceboHaisco Pharmaceutical GroupPhase 2
35
HSK21542 + PlaceboHaisco Pharmaceutical GroupPhase 3
40
HTX-011 + Ibuprofen + Acetaminophen + Celecoxib + +/- Bupivacaine HCl + HTX-011Heron TherapeuticsPhase 3
30
HTX-011 + Bupivacaine Hydrochloride + Ibuprofen + AcetaminophenHeron TherapeuticsApproved
33
HTX-011 + HTX-011 + Ibuprofen + AcetaminophenHeron TherapeuticsPhase 2
25
Bupivacaine HClHeron TherapeuticsApproved
33
HTX-011 + PlaceboHeron TherapeuticsPhase 2
25
HTX-011 + Ibuprofen + AcetaminophenHeron TherapeuticsPhase 3
30
Bupivacaine liposome injectable suspension + Bupivacaine HCl without epinephrine via continuous infusionHeron TherapeuticsApproved
33
HTX-011 + Bupivacaine HCl + HTX-011 + HTX-011 + HTX-011Heron TherapeuticsPhase 2
17